terbutaline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| bronchodilators, phenethylamine derivatives | 2598 | 23031-25-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | mg | Inhal.aerosol |
| 2 | mg | Inhal.powder |
| 20 | mg | Inhal.solution |
| 15 | mg | O |
| 15 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 213 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 56 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.11 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 14 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.50 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 3.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.75 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 15 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 25, 1974 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Asthma | 233.90 | 16.65 | 170 | 8623 | 127391 | 63352838 |
| Dyspnoea | 114.23 | 16.65 | 269 | 8524 | 661044 | 62819185 |
| Wheezing | 98.00 | 16.65 | 91 | 8702 | 95504 | 63384725 |
| Lactic acidosis | 69.87 | 16.65 | 51 | 8742 | 38236 | 63441993 |
| Acute kidney injury | 58.57 | 16.65 | 119 | 8674 | 263296 | 63216933 |
| Sleep disorder due to a general medical condition | 55.20 | 16.65 | 29 | 8764 | 12159 | 63468070 |
| Sputum discoloured | 55.07 | 16.65 | 32 | 8761 | 16315 | 63463914 |
| Middle insomnia | 54.20 | 16.65 | 29 | 8764 | 12614 | 63467615 |
| Nasal discharge discolouration | 51.16 | 16.65 | 17 | 8776 | 2254 | 63477975 |
| Squamous cell carcinoma of the oral cavity | 44.49 | 16.65 | 10 | 8783 | 302 | 63479927 |
| Full blood count abnormal | 37.99 | 16.65 | 33 | 8760 | 31684 | 63448545 |
| Allergy to metals | 35.98 | 16.65 | 10 | 8783 | 725 | 63479504 |
| Iodine allergy | 35.09 | 16.65 | 10 | 8783 | 794 | 63479435 |
| Shock haemorrhagic | 35.00 | 16.65 | 20 | 8773 | 9875 | 63470354 |
| Hyperlactacidaemia | 32.84 | 16.65 | 13 | 8780 | 2836 | 63477393 |
| Forced expiratory volume decreased | 31.93 | 16.65 | 15 | 8778 | 4953 | 63475276 |
| Fallopian tube disorder | 30.77 | 16.65 | 8 | 8785 | 450 | 63479779 |
| Heart rate increased | 30.29 | 16.65 | 50 | 8743 | 94188 | 63386041 |
| Cough | 30.12 | 16.65 | 99 | 8694 | 292644 | 63187585 |
| Obstructive airways disorder | 29.89 | 16.65 | 24 | 8769 | 20675 | 63459554 |
| Exposure during pregnancy | 28.43 | 16.65 | 65 | 8728 | 155482 | 63324747 |
| Productive cough | 28.07 | 16.65 | 39 | 8754 | 63169 | 63417060 |
| Hepatocellular injury | 27.87 | 16.65 | 26 | 8767 | 27355 | 63452874 |
| Tremor | 27.26 | 16.65 | 58 | 8735 | 132181 | 63348048 |
| Bronchospasm | 27.02 | 16.65 | 21 | 8772 | 17259 | 63462970 |
| Alopecia | 26.55 | 16.65 | 7 | 8786 | 337529 | 63142700 |
| Pleural rub | 26.46 | 16.65 | 5 | 8788 | 62 | 63480167 |
| Pneumonia | 26.43 | 16.65 | 129 | 8664 | 456638 | 63023591 |
| Lung diffusion disorder | 25.90 | 16.65 | 5 | 8788 | 70 | 63480159 |
| Eosinophilic granulomatosis with polyangiitis | 25.26 | 16.65 | 10 | 8783 | 2182 | 63478047 |
| Rubber sensitivity | 24.66 | 16.65 | 10 | 8783 | 2321 | 63477908 |
| Foetal exposure during pregnancy | 24.49 | 16.65 | 26 | 8767 | 31936 | 63448293 |
| Folate deficiency | 24.08 | 16.65 | 10 | 8783 | 2465 | 63477764 |
| Post viral fatigue syndrome | 23.55 | 16.65 | 6 | 8787 | 311 | 63479918 |
| Asthmatic crisis | 23.47 | 16.65 | 9 | 8784 | 1804 | 63478425 |
| Nasal congestion | 22.67 | 16.65 | 36 | 8757 | 65624 | 63414605 |
| Cholestasis | 22.65 | 16.65 | 24 | 8769 | 29410 | 63450819 |
| Toxic epidermal necrolysis | 21.92 | 16.65 | 22 | 8771 | 25312 | 63454917 |
| Smoke sensitivity | 21.26 | 16.65 | 6 | 8787 | 460 | 63479769 |
| Phlebectomy | 20.78 | 16.65 | 4 | 8789 | 55 | 63480174 |
| Joint swelling | 20.33 | 16.65 | 10 | 8783 | 327656 | 63152573 |
| Contraindicated product administered | 20.26 | 16.65 | 3 | 8790 | 217645 | 63262584 |
| Spirometry abnormal | 20.08 | 16.65 | 5 | 8788 | 236 | 63479993 |
| Eosinophil count abnormal | 19.88 | 16.65 | 6 | 8787 | 582 | 63479647 |
| Premature baby | 19.79 | 16.65 | 19 | 8774 | 20716 | 63459513 |
| Premature separation of placenta | 19.74 | 16.65 | 8 | 8785 | 1853 | 63478376 |
| Respiratory tract inflammation | 19.72 | 16.65 | 6 | 8787 | 598 | 63479631 |
| Neonatal respiratory distress syndrome | 19.64 | 16.65 | 9 | 8784 | 2809 | 63477420 |
| Haematoma | 19.36 | 16.65 | 24 | 8769 | 34796 | 63445433 |
| Forced expiratory volume abnormal | 19.28 | 16.65 | 4 | 8789 | 82 | 63480147 |
| Loss of personal independence in daily activities | 19.27 | 16.65 | 42 | 8751 | 97248 | 63382981 |
| Systemic lupus erythematosus | 19.17 | 16.65 | 3 | 8790 | 208915 | 63271314 |
| Allergy to animal | 19.10 | 16.65 | 7 | 8786 | 1239 | 63478990 |
| Exposure to allergen | 18.52 | 16.65 | 5 | 8788 | 325 | 63479904 |
| Eosinophilia | 18.30 | 16.65 | 19 | 8774 | 22737 | 63457492 |
| Respiratory distress | 18.23 | 16.65 | 23 | 8770 | 33928 | 63446301 |
| Respiratory rate increased | 17.97 | 16.65 | 15 | 8778 | 13633 | 63466596 |
| Chest discomfort | 17.96 | 16.65 | 44 | 8749 | 109925 | 63370304 |
| Tachycardia | 17.96 | 16.65 | 46 | 8747 | 118110 | 63362119 |
| Seasonal allergy | 17.77 | 16.65 | 18 | 8775 | 20932 | 63459297 |
| Renal tubular necrosis | 17.63 | 16.65 | 14 | 8779 | 11864 | 63468365 |
| Polyp | 17.41 | 16.65 | 11 | 8782 | 6510 | 63473719 |
| Therapeutic product effect incomplete | 17.29 | 16.65 | 47 | 8746 | 125009 | 63355220 |
| Hyperkinesia | 16.97 | 16.65 | 7 | 8786 | 1697 | 63478532 |
| Blood pressure increased | 16.80 | 16.65 | 55 | 8738 | 162007 | 63318222 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Asthma | 143.24 | 19.00 | 85 | 5068 | 42571 | 34909207 |
| Wheezing | 95.21 | 19.00 | 65 | 5088 | 41337 | 34910441 |
| Blood immunoglobulin E increased | 76.22 | 19.00 | 24 | 5129 | 2522 | 34949256 |
| Cholestasis | 65.94 | 19.00 | 44 | 5109 | 26904 | 34924874 |
| Chest discomfort | 62.93 | 19.00 | 57 | 5096 | 54473 | 34897305 |
| Dyspnoea | 59.55 | 19.00 | 154 | 4999 | 376628 | 34575150 |
| Rhinitis | 48.48 | 19.00 | 22 | 5131 | 6316 | 34945462 |
| Hyperkaliuria | 48.40 | 19.00 | 9 | 5144 | 95 | 34951683 |
| Forced expiratory volume decreased | 48.04 | 19.00 | 18 | 5135 | 3185 | 34948593 |
| Obstructive airways disorder | 47.05 | 19.00 | 29 | 5124 | 15465 | 34936313 |
| Wolff-Parkinson-White syndrome | 41.43 | 19.00 | 9 | 5144 | 217 | 34951561 |
| Exposure during pregnancy | 41.30 | 19.00 | 22 | 5131 | 8912 | 34942866 |
| Agranulocytosis | 37.94 | 19.00 | 30 | 5123 | 23791 | 34927987 |
| Nasal disorder | 37.00 | 19.00 | 13 | 5140 | 1915 | 34949863 |
| Bronchospasm | 34.92 | 19.00 | 21 | 5132 | 10710 | 34941068 |
| Asthma-chronic obstructive pulmonary disease overlap syndrome | 33.86 | 19.00 | 11 | 5142 | 1276 | 34950502 |
| Toxic epidermal necrolysis | 31.79 | 19.00 | 26 | 5127 | 21620 | 34930158 |
| Gastrointestinal mucosal necrosis | 31.61 | 19.00 | 7 | 5146 | 185 | 34951593 |
| Sputum increased | 30.80 | 19.00 | 12 | 5141 | 2358 | 34949420 |
| Cough | 27.34 | 19.00 | 65 | 5088 | 150075 | 34801703 |
| Meralgia paraesthetica | 27.26 | 19.00 | 6 | 5147 | 154 | 34951624 |
| Placental transfusion syndrome | 26.90 | 19.00 | 4 | 5149 | 8 | 34951770 |
| Bronchospasm paradoxical | 26.54 | 19.00 | 5 | 5148 | 57 | 34951721 |
| Penile erythema | 26.36 | 19.00 | 6 | 5147 | 180 | 34951598 |
| Unmasking of previously unidentified disease | 24.81 | 19.00 | 8 | 5145 | 906 | 34950872 |
| Nasal inflammation | 24.03 | 19.00 | 6 | 5147 | 269 | 34951509 |
| Death | 23.40 | 19.00 | 15 | 5138 | 398034 | 34553744 |
| Foetal distress syndrome | 23.36 | 19.00 | 8 | 5145 | 1092 | 34950686 |
| Heart rate increased | 22.77 | 19.00 | 31 | 5122 | 46312 | 34905466 |
| Cyanosis | 22.32 | 19.00 | 17 | 5136 | 12747 | 34939031 |
| Prothrombin time ratio decreased | 21.96 | 19.00 | 6 | 5147 | 383 | 34951395 |
| Premature baby | 21.58 | 19.00 | 20 | 5133 | 19613 | 34932165 |
| Middle insomnia | 21.33 | 19.00 | 13 | 5140 | 6789 | 34944989 |
| Stillbirth | 21.11 | 19.00 | 5 | 5148 | 179 | 34951599 |
| Hepatic vein occlusion | 21.06 | 19.00 | 5 | 5148 | 181 | 34951597 |
| Respiratory distress | 20.86 | 19.00 | 26 | 5127 | 35639 | 34916139 |
| Subcapsular splenic haematoma | 20.03 | 19.00 | 4 | 5149 | 63 | 34951715 |
| Lung disorder | 19.82 | 19.00 | 25 | 5128 | 34671 | 34917107 |
| Ductus arteriosus premature closure | 19.38 | 19.00 | 5 | 5148 | 256 | 34951522 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Asthma | 248.70 | 14.98 | 192 | 12672 | 134903 | 79596621 |
| Wheezing | 158.32 | 14.98 | 139 | 12725 | 116525 | 79614999 |
| Dyspnoea | 122.78 | 14.98 | 358 | 12506 | 856667 | 78874857 |
| Cholestasis | 82.70 | 14.98 | 68 | 12796 | 52041 | 79679483 |
| Forced expiratory volume decreased | 76.04 | 14.98 | 33 | 12831 | 7781 | 79723743 |
| Lactic acidosis | 74.37 | 14.98 | 73 | 12791 | 70286 | 79661238 |
| Obstructive airways disorder | 67.26 | 14.98 | 49 | 12815 | 31410 | 79700114 |
| Middle insomnia | 66.67 | 14.98 | 38 | 12826 | 16031 | 79715493 |
| Chest discomfort | 62.40 | 14.98 | 93 | 12771 | 137951 | 79593573 |
| Bronchospasm | 58.38 | 14.98 | 41 | 12823 | 24818 | 79706706 |
| Blood immunoglobulin E increased | 57.76 | 14.98 | 25 | 12839 | 5857 | 79725667 |
| Cough | 56.74 | 14.98 | 158 | 12706 | 366631 | 79364893 |
| Sputum discoloured | 56.10 | 14.98 | 38 | 12826 | 21705 | 79709819 |
| Heart rate increased | 52.65 | 14.98 | 80 | 12784 | 120644 | 79610880 |
| Toxic epidermal necrolysis | 50.37 | 14.98 | 48 | 12816 | 44533 | 79686991 |
| Shock haemorrhagic | 44.59 | 14.98 | 32 | 12832 | 20028 | 79711496 |
| Nasal discharge discolouration | 43.17 | 14.98 | 16 | 12848 | 2505 | 79729019 |
| Hyperkaliuria | 42.76 | 14.98 | 9 | 12855 | 169 | 79731355 |
| Productive cough | 42.04 | 14.98 | 61 | 12803 | 88270 | 79643254 |
| Acute kidney injury | 41.79 | 14.98 | 180 | 12684 | 519224 | 79212300 |
| Wolff-Parkinson-White syndrome | 37.99 | 14.98 | 9 | 12855 | 294 | 79731230 |
| Squamous cell carcinoma of the oral cavity | 37.75 | 14.98 | 10 | 12854 | 518 | 79731006 |
| Bronchospasm paradoxical | 37.44 | 14.98 | 8 | 12856 | 162 | 79731362 |
| Full blood count abnormal | 37.28 | 14.98 | 39 | 12825 | 40435 | 79691089 |
| Sleep disorder due to a general medical condition | 36.94 | 14.98 | 25 | 12839 | 14252 | 79717272 |
| Rhinitis | 36.11 | 14.98 | 25 | 12839 | 14782 | 79716742 |
| Nasal congestion | 32.33 | 14.98 | 50 | 12814 | 76502 | 79655022 |
| Hepatocellular injury | 32.10 | 14.98 | 39 | 12825 | 47554 | 79683970 |
| Eosinophilic granulomatosis with polyangiitis | 30.92 | 14.98 | 14 | 12850 | 3646 | 79727878 |
| Hyperlactacidaemia | 30.91 | 14.98 | 16 | 12848 | 5579 | 79725945 |
| Nasal disorder | 30.53 | 14.98 | 14 | 12850 | 3755 | 79727769 |
| Fallopian tube disorder | 30.34 | 14.98 | 8 | 12856 | 407 | 79731117 |
| Gastrointestinal mucosal necrosis | 29.72 | 14.98 | 7 | 12857 | 223 | 79731301 |
| Drug intolerance | 29.20 | 14.98 | 4 | 12860 | 264115 | 79467409 |
| Small intestinal haemorrhage | 29.20 | 14.98 | 14 | 12850 | 4149 | 79727375 |
| Agranulocytosis | 27.33 | 14.98 | 35 | 12829 | 44995 | 79686529 |
| Death | 27.02 | 14.98 | 31 | 12833 | 566483 | 79165041 |
| Penile erythema | 26.80 | 14.98 | 6 | 12858 | 152 | 79731372 |
| Haematoma | 26.22 | 14.98 | 37 | 12827 | 52158 | 79679366 |
| Respiratory distress | 25.89 | 14.98 | 39 | 12825 | 58300 | 79673224 |
| Pleural rub | 25.48 | 14.98 | 5 | 12859 | 65 | 79731459 |
| Blood pressure increased | 25.03 | 14.98 | 83 | 12781 | 211277 | 79520247 |
| Tremor | 24.98 | 14.98 | 72 | 12792 | 170011 | 79561513 |
| Sputum increased | 24.94 | 14.98 | 13 | 12851 | 4600 | 79726924 |
| Lung disorder | 23.93 | 14.98 | 45 | 12819 | 80512 | 79651012 |
| Bronchitis | 23.91 | 14.98 | 60 | 12804 | 130584 | 79600940 |
| Respiratory rate increased | 23.91 | 14.98 | 23 | 12841 | 21577 | 79709947 |
| Asthma-chronic obstructive pulmonary disease overlap syndrome | 23.10 | 14.98 | 11 | 12853 | 3210 | 79728314 |
| Smoke sensitivity | 22.89 | 14.98 | 7 | 12857 | 609 | 79730915 |
| Forced expiratory volume abnormal | 22.28 | 14.98 | 5 | 12859 | 128 | 79731396 |
| Post viral fatigue syndrome | 22.07 | 14.98 | 6 | 12858 | 343 | 79731181 |
| Alopecia | 20.39 | 14.98 | 6 | 12858 | 231349 | 79500175 |
| Lung diffusion disorder | 20.35 | 14.98 | 5 | 12859 | 191 | 79731333 |
| Increased bronchial secretion | 19.79 | 14.98 | 10 | 12854 | 3317 | 79728207 |
| Folate deficiency | 19.70 | 14.98 | 10 | 12854 | 3350 | 79728174 |
| Meralgia paraesthetica | 19.64 | 14.98 | 6 | 12858 | 520 | 79731004 |
| Hepatic vein occlusion | 19.58 | 14.98 | 5 | 12859 | 224 | 79731300 |
| Breath sounds abnormal | 19.57 | 14.98 | 18 | 12846 | 15966 | 79715558 |
| Sinus tachycardia | 18.30 | 14.98 | 26 | 12838 | 36882 | 79694642 |
| Asthmatic crisis | 17.99 | 14.98 | 8 | 12856 | 1998 | 79729526 |
| Systolic hypertension | 17.88 | 14.98 | 6 | 12858 | 702 | 79730822 |
| Urticaria | 17.86 | 14.98 | 68 | 12796 | 185133 | 79546391 |
| Unmasking of previously unidentified disease | 17.80 | 14.98 | 8 | 12856 | 2049 | 79729475 |
| Nasal inflammation | 17.73 | 14.98 | 6 | 12858 | 721 | 79730803 |
| Exposure to allergen | 17.60 | 14.98 | 5 | 12859 | 336 | 79731188 |
| Eosinophil count abnormal | 17.54 | 14.98 | 6 | 12858 | 745 | 79730779 |
| Decreased activity | 17.36 | 14.98 | 13 | 12851 | 8681 | 79722843 |
| Pneumonia | 17.11 | 14.98 | 172 | 12692 | 660074 | 79071450 |
| Allergy to animal | 17.08 | 14.98 | 7 | 12857 | 1432 | 79730092 |
| Joint swelling | 17.02 | 14.98 | 13 | 12851 | 288633 | 79442891 |
| Embolism arterial | 16.72 | 14.98 | 7 | 12857 | 1511 | 79730013 |
| Prothrombin time ratio decreased | 16.32 | 14.98 | 6 | 12858 | 919 | 79730605 |
| Cyanosis | 15.95 | 14.98 | 20 | 12844 | 25162 | 79706362 |
| Polyp | 15.91 | 14.98 | 12 | 12852 | 8095 | 79723429 |
| Eosinophilia | 15.59 | 14.98 | 27 | 12837 | 45318 | 79686206 |
| Dermatitis bullous | 15.45 | 14.98 | 15 | 12849 | 14230 | 79717294 |
| Rash maculo-papular | 15.03 | 14.98 | 30 | 12834 | 56048 | 79675476 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | R03AC03 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Selective beta-2-adrenoreceptor agonists |
| ATC | R03CC03 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Selective beta-2-adrenoreceptor agonists |
| ATC | R03CC53 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Selective beta-2-adrenoreceptor agonists |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D000322 | Adrenergic Agonists |
| MeSH PA | D058666 | Adrenergic beta-2 Receptor Agonists |
| MeSH PA | D000318 | Adrenergic beta-Agonists |
| MeSH PA | D018927 | Anti-Asthmatic Agents |
| MeSH PA | D001993 | Bronchodilator Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D012102 | Reproductive Control Agents |
| MeSH PA | D019141 | Respiratory System Agents |
| MeSH PA | D013566 | Sympathomimetics |
| MeSH PA | D015149 | Tocolytic Agents |
| CHEBI has role | CHEBI:35522 | beta-adrenergic agonists |
| CHEBI has role | CHEBI:35523 | bronchodilator |
| CHEBI has role | CHEBI:35524 | sympathomimetic |
| CHEBI has role | CHEBI:35526 | antidiabetic |
| CHEBI has role | CHEBI:38462 | acetylcholinesterase inhibitors |
| CHEBI has role | CHEBI:49167 | anti-asthmatic drugs |
| CHEBI has role | CHEBI:66993 | tocolytic drugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Bronchitis | indication | 32398004 | DOID:6132 |
| Tear film insufficiency | indication | 46152009 | |
| Pulmonary emphysema | indication | 87433001 | |
| Asthma | indication | 195967001 | DOID:2841 |
| Skin irritation | indication | 367466007 | |
| Asthma management | indication | 406162001 | |
| Itching of skin | indication | 418363000 | |
| Acute exacerbation of asthma | indication | 708038006 | |
| Chronic Obstructive Pulmonary Disease with Bronchospasms | indication | ||
| Minor Skin Wound Pain | indication | ||
| Bronchospasm Prevention | indication | ||
| Premature labor | off-label use | 6383007 | |
| Bronchiectasis | off-label use | 12295008 | DOID:9563 |
| Keratoconjunctivitis sicca | off-label use | 302896008 | DOID:12895 |
| Pulmonary edema | contraindication | 19242006 | DOID:11396 |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Hypokalemia | contraindication | 43339004 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Ketoacidosis | contraindication | 56051008 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Compression of umbilical cord | contraindication | 79222000 | |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Decreased respiratory function | contraindication | 80954004 | |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Open wound | contraindication | 125643001 | |
| Seizure disorder | contraindication | 128613002 | |
| Chronic myocardial ischemia | contraindication | 413844008 | DOID:3393 |
| Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
| Placental abruption | contraindication | 415105001 | |
| Denuded skin | contraindication | 418242004 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.48 | acidic |
| pKa2 | 11.49 | acidic |
| pKa3 | 12.74 | acidic |
| pKa4 | 8.66 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-2 adrenergic receptor | GPCR | AGONIST | Ki | 5.60 | WOMBAT-PK | CHEMBL | |||
| Beta-2 adrenergic receptor | GPCR | Kd | 5.40 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019941 | VUID |
| N0000148026 | NUI |
| D00688 | KEGG_DRUG |
| 23031-32-5 | SECONDARY_CAS_RN |
| 4018396 | VANDF |
| 4019941 | VANDF |
| C0039542 | UMLSCUI |
| CHEBI:9449 | CHEBI |
| CHEMBL1760 | ChEMBL_ID |
| DB00871 | DRUGBANK_ID |
| CHEMBL1315867 | ChEMBL_ID |
| CHEMBL1160544 | ChEMBL_ID |
| D013726 | MESH_DESCRIPTOR_UI |
| 5403 | PUBCHEM_CID |
| 560 | IUPHAR_LIGAND_ID |
| 2616 | INN_ID |
| N8ONU3L3PG | UNII |
| 10368 | RXNORM |
| 41721 | MMSL |
| 5548 | MMSL |
| d00752 | MMSL |
| 001812 | NDDF |
| 004731 | NDDF |
| 24583009 | SNOMEDCT_US |
| 372745006 | SNOMEDCT_US |
| 45311002 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| TERBUTALINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-2611 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
| TERBUTALINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-2622 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9375 | INJECTION | 1 mg | SUBCUTANEOUS | ANDA | 22 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9375 | INJECTION | 1 mg | SUBCUTANEOUS | ANDA | 22 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9746 | INJECTION | 1 mg | SUBCUTANEOUS | ANDA | 22 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9746 | INJECTION | 1 mg | SUBCUTANEOUS | ANDA | 22 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9962 | INJECTION, SOLUTION | 1 mg | SUBCUTANEOUS | ANDA | 11 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9962 | INJECTION, SOLUTION | 1 mg | SUBCUTANEOUS | ANDA | 11 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9962 | INJECTION, SOLUTION | 1 mg | SUBCUTANEOUS | ANDA | 11 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1311 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1311 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1318 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1318 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-579 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-580 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10271-101 | INJECTION | 1 mg | SUBCUTANEOUS | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-933 | INJECTION | 1 mg | SUBCUTANEOUS | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-121 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-122 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-132 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-132 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-133 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-133 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52584-665 | INJECTION, SOLUTION | 1 mg | SUBCUTANEOUS | ANDA | 11 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52584-665 | INJECTION, SOLUTION | 1 mg | SUBCUTANEOUS | ANDA | 11 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0312 | TABLET | 2.50 mg | ORAL | ANDA | 22 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-524 | TABLET | 2.50 mg | ORAL | ANDA | 13 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-525 | TABLET | 5 mg | ORAL | ANDA | 13 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-721 | TABLET | 2.50 mg | ORAL | NDA authorized generic | 22 sections |
| Terbutaline Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-722 | TABLET | 5 mg | ORAL | NDA authorized generic | 22 sections |